GOSSAMER BIO, INC. Revenue
GOSSAMER BIO, INC. (GOSS) reported Revenue of $9.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- GOSSAMER BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $9.24M, a 19.59% decline year-over-year.
- GOSSAMER BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $16.95M, a 71.45% increase year-over-year.
- GOSSAMER BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $13.80M, a 47.13% increase year-over-year.
- GOSSAMER BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $13.29M, a 40.23% increase year-over-year.
- GOSSAMER BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $48.47M, a 57.74% decline from fiscal 2024.
- GOSSAMER BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $114.70M.
- GOSSAMER BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $0.00.
- GOSSAMER BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.24M 10-Q · filed 2026-08-13 | $26.19M 10-Q · filed 2026-08-13 | $39.99M derived: sum of 3 quarters · filed 2026-08-13 | $53.29M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $16.95M 10-Q · filed 2026-05-15 | $30.75M derived: sum of 2 quarters · filed 2026-05-15 | $44.05M derived: sum of 3 quarters · filed 2026-05-15 | $55.54M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $13.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $27.09M derived: sum of 2 quarters · filed 2026-03-17 | $38.58M derived: sum of 3 quarters · filed 2026-08-13 | $48.47M 10-K · filed 2026-03-17 |
| 2025-09-30 | $13.29M 10-Q · filed 2025-11-05 | $24.78M derived: sum of 2 quarters · filed 2026-08-13 | $34.67M 10-Q · filed 2025-11-05 | $44.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $11.49M 10-Q · filed 2026-08-13 | $21.38M 10-Q · filed 2026-08-13 | $30.76M derived: sum of 3 quarters · filed 2026-08-13 | $40.24M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $9.89M 10-Q · filed 2026-05-15 | $19.27M derived: sum of 2 quarters · filed 2026-05-15 | $28.75M derived: sum of 3 quarters · filed 2026-05-15 | $124.59M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $9.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $18.86M derived: sum of 2 quarters · filed 2026-03-17 | $114.70M derived: sum of 3 quarters · filed 2026-03-17 | $114.70M 10-K · filed 2026-03-17 |
| 2024-09-30 | $9.48M 10-Q · filed 2025-11-05 | $105.32M derived: sum of 2 quarters · filed 2025-11-05 | $105.32M 10-Q · filed 2025-11-05 | $105.32M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $95.84M 10-Q · filed 2025-08-05 | $95.84M 10-Q · filed 2025-08-05 | $95.84M derived: sum of 3 quarters · filed 2026-03-17 | $95.84M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 10-K · filed 2026-03-17 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |